Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: The diagnosis of nodal nevi (NN) is challenging as they mimic melanoma metastases (MM), with a detection rate mostly ranging between 1% and 11% in sentinel lymph node biopsy (SLNB). Herein, we assessed the incidence of NN and the association with the clinical-pathological features of primary melanoma, adopting the updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for SLNB.

Methods: All cases of paired melanoma and SLNB were retrospectively evaluated (April 2019-May 2020). Appropriate statistical tests were adopted, with significant variables included in the logistic regression model.

Results: 81 patients and a total of 186 lymph nodes (LNs) were included. Eleven patients had only NN and 4 had both NN and MM (18.5%); 29 LNs (15.6%) showed at least one NN and 12 (6.5%) showed more than one NN (a total amount of 43 NN was detected). All NN and none MM stained for p16. NN were associated with age < 60 years (p: 0.042), no ulceration (p: 0.025) and nevus-associated melanoma (NAM) (p: 0.018), with this latter being the only predictor at the logistic regression model (p: 0.022).

Conclusions: The updated EORTC protocol shows a high number of NN and highlights a strong association with NAM.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prp.2022.153805DOI Listing

Publication Analysis

Top Keywords

eortc protocol
8
sentinel lymph
8
lymph node
8
node biopsy
8
biopsy slnb
8
nodal nevi
8
protocol sentinel
4
slnb reveals
4
reveals high
4
high number
4

Similar Publications

Methodological Insights from Health Valuation Studies in Low- and Middle-Income Countries: A Scoping Review.

Value Health

September 2025

Health Systems Research Unit, South African Medical Research Council, Cape Town, South Africa.

Objectives: Valuation studies generate utility values for health states using stated preference methods. These studies are complex and resource intensive, posing implementation challenges in low- and middle-income countries (LMICs). This review aimed to examine how valuation studies in LMICs have navigated these challenges.

View Article and Find Full Text PDF

Background: No standard treatment exists for patients with platinum-refractory advanced type B3 thymoma and thymic carcinoma. In the PECATI trial, we sought to assess the antitumour activity and safety of lenvatinib plus pembrolizumab in this population.

Methods: In this single-arm phase 2 trial, we recruited participants from 11 hospitals in France, Italy, and Spain.

View Article and Find Full Text PDF

Aim: Total neoadjuvant therapy (TNT) for locally advanced rectal cancer improves oncological outcomes and organ preservation rates, but the impact on patient quality of life (QoL) is not known. This cohort study compares the quality of life (QoL) of post-TNT watch-and-wait (W&W) patients to a historical cohort of patients that underwent standard care.

Method: Patients managed with a W&W approach following a personalised TNT (pTNT W&W group) were compared with historical group patients who had undergone standard treatment but who would have been eligible for pTNT under our current protocol (STD group).

View Article and Find Full Text PDF

Background: (1→3)-β-D-glucan (BDG), a component of the fungal cell wall, has emerged as a potential cerebrospinal fluid (CSF) biomarker for fungal infections of the central nervous system (FI-CNS). While the Fungitell® assay has been well studied in this context, the diagnostic performance of the Fujifilm Wako β-glucan assay in CSF remains unknown. The present study aimed to evaluate the Fujifilm Wako assay for diagnosing non-cryptococcal FI-CNS, establish an optimal CSF-specific BDG cut-off value, and assess its concordance with the Fungitell® assay.

View Article and Find Full Text PDF

Introduction: Patients' QoL scores during chemotherapy are generally measured during hospital visits. However, patients frequently recover from AEs before hospital arrival. This study continuously assessed each chemotherapy's impact on patients' QoL scores during hospital visits and at home using an electronic device (ePRO).

View Article and Find Full Text PDF